Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 36.00 | |
50 mg | In stock | $ 52.00 | |
100 mg | In stock | $ 81.00 | |
200 mg | In stock | $ 123.00 | |
500 mg | In stock | $ 189.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 39.00 |
Description | Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice. |
In vitro | In a mouse model simulating human disease, treatment with Moxifloxacin combined with RIF (Rifampicin)/PZA (Pyrazinamide) shortened the therapy duration by two months compared to the standard regimen of INH (Isoniazid)/RIF/PZA. Similarly, biweekly administration of Rifampicin/Moxifloxacin/PZA led to stable cure after four months, whereas daily treatment with Rifampicin/INH/PZA resulted in cure after six months. |
In vivo | Moxifloxacin exhibits a broad spectrum of antibacterial activity both in vitro and clinically against various pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. It functions by stabilizing the DNA-drug-enzyme complex, thereby inhibiting ATP-dependent topoisomerase II (DNA gyrase) and topoisomerase IV, critical enzymes for bacterial DNA replication, transcription, repair, and recombination. |
Synonyms | BAY-128039, Moxifloxacin HCl, BAY12-8039 HCl |
Molecular Weight | 437.89 |
Formula | C21H25ClFN3O4 |
CAS No. | 186826-86-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 15 mg/mL(34.3 mM)
DMSO: 88 mg/mL (200.96 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Moxifloxacin hydrochloride 186826-86-8 DNA Damage/DNA Repair Microbiology/Virology Antibiotic Antibacterial Topoisomerase Moxifloxacin exacerbations bronchitis BAY 128039 community-acquired chronic acute BAY-128039 Moxifloxacin Hydrochloride sinusitis BAY128039 antimicrobial BAY 12-8039 Bacterial inhibit Moxifloxacin HCl 8-methoxyquinolone BAY12-8039 HCl Inhibitor pneumonia inhibitor